Replies to post #548 on Israel-Medical-Healthcare

[DewDiligence]

> Quark Biotech – "We paid more than $95 million in royalties to two companies for the purchase of a license for drugs that we developed… That is why the deal with Pfizer is worth hundreds of millions of dollars,"<

These two companies are SR Pharma (#msg-13597890) and ALNY (#msg-13575078). From the contents of these two PR’s, it appears that SR Pharma is the main sublicensing beneficiary and ALNY’s take is small.

Still, no matter how you slice it the PFE-Quark deal is a big story for RNAi (and for Israel).